Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P49585
UPID:
PCY1A_HUMAN
Alternative names:
CCT-alpha; CTP:phosphocholine cytidylyltransferase A; Phosphorylcholine transferase A
Alternative UPACC:
P49585; A9LYK9; D3DXB1; Q86Y88
Background:
Choline-phosphate cytidylyltransferase A, also known as CCT-alpha, plays a pivotal role in the CDP-choline pathway, crucial for phosphatidylcholine biosynthesis. This enzyme's activity is essential for maintaining cellular membrane integrity and facilitating lipid metabolism.
Therapeutic significance:
The enzyme's mutation is linked to Spondylometaphyseal dysplasia with cone-rod dystrophy, a disorder marked by growth deficiency and visual impairment. Understanding the role of Choline-phosphate cytidylyltransferase A could open doors to potential therapeutic strategies.